288 related articles for article (PubMed ID: 15505150)
1. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.
Brooks BR; Thisted RA; Appel SH; Bradley WG; Olney RK; Berg JE; Pope LE; Smith RA;
Neurology; 2004 Oct; 63(8):1364-70. PubMed ID: 15505150
[TBL] [Abstract][Full Text] [Related]
2. Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
Patatanian E; Casselman J
Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895
[TBL] [Abstract][Full Text] [Related]
3. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
Hammond FM; Alexander DN; Cutler AJ; D'Amico S; Doody RS; Sauve W; Zorowitz RD; Davis CS; Shin P; Ledon F; Yonan C; Formella AE; Siffert J
BMC Neurol; 2016 Jun; 16():89. PubMed ID: 27276999
[TBL] [Abstract][Full Text] [Related]
4. Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study.
Hammond FM; Sauve W; Ledon F; Davis C; Formella AE
PM R; 2018 Oct; 10(10):993-1003. PubMed ID: 29477412
[TBL] [Abstract][Full Text] [Related]
5. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
Pattee GL; Wymer JP; Lomen-Hoerth C; Appel SH; Formella AE; Pope LE
Curr Med Res Opin; 2014 Nov; 30(11):2255-65. PubMed ID: 25062507
[TBL] [Abstract][Full Text] [Related]
6. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.
Panitch HS; Thisted RA; Smith RA; Wynn DR; Wymer JP; Achiron A; Vollmer TL; Mandler RN; Dietrich DW; Fletcher M; Pope LE; Berg JE; Miller A;
Ann Neurol; 2006 May; 59(5):780-7. PubMed ID: 16634036
[TBL] [Abstract][Full Text] [Related]
7. Treatment of pseudobulbar affect in ALS.
Smith RA; Brooks BR
Lancet Neurol; 2005 May; 4(5):270. PubMed ID: 15847840
[No Abstract] [Full Text] [Related]
8. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
Doody RS; D'Amico S; Cutler AJ; Davis CS; Shin P; Ledon F; Yonan C; Siffert J
CNS Spectr; 2016 Dec; 21(6):450-459. PubMed ID: 26471212
[TBL] [Abstract][Full Text] [Related]
9. Treatment of pseudobulbar affect in ALS: October 26 highlight and commentary.
Hingorani VN; Kittrelle JP
Neurology; 2005 May; 64(10):1821; author reply 1821. PubMed ID: 15911831
[No Abstract] [Full Text] [Related]
10. Dextromethorphan/quinidine: in pseudobulbar affect.
Garnock-Jones KP
CNS Drugs; 2011 May; 25(5):435-45. PubMed ID: 21476614
[TBL] [Abstract][Full Text] [Related]
11. Dextromethorphan/quinidine sulfate for pseudobulbar affect.
Rosen H
Drugs Today (Barc); 2008 Sep; 44(9):661-8. PubMed ID: 19137121
[TBL] [Abstract][Full Text] [Related]
12. AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain.
Olney N; Rosen H
IDrugs; 2010 Apr; 13(4):254-65. PubMed ID: 20373255
[TBL] [Abstract][Full Text] [Related]
13. Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect.
Haiman G; Pratt H; Miller A
J Clin Psychopharmacol; 2009 Oct; 29(5):444-52. PubMed ID: 19745644
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.
Fralick M; Sacks CA; Kesselheim AS
JAMA Intern Med; 2019 Feb; 179(2):224-230. PubMed ID: 30615021
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.
Pope LE; Khalil MH; Berg JE; Stiles M; Yakatan GJ; Sellers EM
J Clin Pharmacol; 2004 Oct; 44(10):1132-42. PubMed ID: 15342614
[TBL] [Abstract][Full Text] [Related]
16. Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.
Pioro EP
Neurol Ther; 2014 Jun; 3(1):15-28. PubMed ID: 26000221
[TBL] [Abstract][Full Text] [Related]
17. Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis.
Sancho J; Ferrer S; Burés E; Luis Díaz J; Torrecilla T; Signes-Costa J; Servera E
Respir Med; 2021 Sep; 186():106536. PubMed ID: 34260979
[TBL] [Abstract][Full Text] [Related]
18. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J
Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect.
Miller A; Panitch H
J Neurol Sci; 2007 Aug; 259(1-2):67-73. PubMed ID: 17433820
[TBL] [Abstract][Full Text] [Related]
20. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.
Pioro EP; Brooks BR; Cummings J; Schiffer R; Thisted RA; Wynn D; Hepner A; Kaye R;
Ann Neurol; 2010 Nov; 68(5):693-702. PubMed ID: 20839238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
